Shunchao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shunchao Zhang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bingjie Guan
Henan University of Chinese Medicine, Zhengzhou 450046, Henan, China
1 shared publication - Chunguang Li
Henan University of Chinese Medicine, Zhengzhou 450046, Henan, China
1 shared publication - Haoran Qu
Henan University of Chinese Medicine, Zhengzhou 450046, Henan, China
1 shared publication - Juntao Wang
Department of oncology, People’s Hospital of Henan University of Chinese Medicine, Zhengzhou, China
1 shared publication - Mengya Liu
Department of Oncology, Ward 2, The Third Affiliated Hospital of Henan, University of Chinese Medicine, Zhengzhou 450008, Henan, China
1 shared publication - Yuhan Wei
School of Acupuncture, Moxibustion and Tuina, Henan University of Chinese Medicine, Zhengzhou 450046, Henan, China
1 shared publication
Latest Publications
- 28 January 2026
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 54 (01) , 139-169
Research Progress on Combination Therapies Based on PD-1/PD-L1 Blockade Against Malignancies and the Adjuvant Effects of Traditional Chinese Medicine
Programmed death (PD-1) is an important immune checkpoint receptor expressed on the surface of T cells, B cells and natural killer (NK) cells. PD-L1 (B7-H1) is a critical ligand for PD-1, and is widely expressed in a variety of cancer cells, immune cells, and normal histocytes. It has been established that the PD-1/PD-L1 interaction can produce an immunosuppressive effect by suppressing T cell proliferation, cytokine secretion, and cytotoxicity. Currently, PD-1 and PD-L1 inhibitors are known to be promising anticancer agents that reverse the antitumor immune function of T cells by inhibiting the PD-1/PD-L1 axis. The monotherapy of PD-1/PD-L1 blockade, while effective in treating cancers, is limited by a low response rate, immune-related adverse events (irAEs), and drug resistance. Their combinations with surgery, chemotherapy, radiotherapy, immunotherapy, hormone therapy, and traditional Chinese medicine (TCM), due to a synergistic effect, have broadened the frontier of cancer research. Following a holistic principle, TCM serves as an adjuvant therapy with PD-1/PD-L1 blockade, and provides benefits through complicated mechanisms. We specifically focused on the profound significance of TCM’s assistance of PD-1/PD-L1 blockade, and the opportunities and challenges of treating cancers with both TCM and PD-1/PD-L1 blockade.
- 28 January 2026
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 54 (01) , 139-169
Research Progress on Combination Therapies Based on PD-1/PD-L1 Blockade Against Malignancies and the Adjuvant Effects of Traditional Chinese Medicine
Programmed death (PD-1) is an important immune checkpoint receptor expressed on the surface of T cells, B cells and natural killer (NK) cells. PD-L1 (B7-H1) is a critical ligand for PD-1, and is widely expressed in a variety of cancer cells, immune cells, and normal histocytes. It has been established that the PD-1/PD-L1 interaction can produce an immunosuppressive effect by suppressing T cell proliferation, cytokine secretion, and cytotoxicity. Currently, PD-1 and PD-L1 inhibitors are known to be promising anticancer agents that reverse the antitumor immune function of T cells by inhibiting the PD-1/PD-L1 axis. The monotherapy of PD-1/PD-L1 blockade, while effective in treating cancers, is limited by a low response rate, immune-related adverse events (irAEs), and drug resistance. Their combinations with surgery, chemotherapy, radiotherapy, immunotherapy, hormone therapy, and traditional Chinese medicine (TCM), due to a synergistic effect, have broadened the frontier of cancer research. Following a holistic principle, TCM serves as an adjuvant therapy with PD-1/PD-L1 blockade, and provides benefits through complicated mechanisms. We specifically focused on the profound significance of TCM’s assistance of PD-1/PD-L1 blockade, and the opportunities and challenges of treating cancers with both TCM and PD-1/PD-L1 blockade.